i think that's right. our "credibility" bank account was

New Post Public Reply Private Reply Replies (3) Message Board
Hulk767 Evil Rabbit #136383
618
i think that's right. our "credibility" bank account was way overdrawn for years under NP / Amarex. As you said, we received very specific guidance from the FDA more than once - and yet continued to submit flawed and incomplete data via Amarex. Add to that Nader's way over the top promotional approach, 3-finger / 3 figure stock predictions, and the partnership with Martin Shkreli, and it's easy to see why we were viewed as a problem child by the FDA.

before going on leave, Cyrus was doing exactly what needed to be done, and had turned this around almost totally - and was a long way down the path of restoring our credibility - he knew how important this was, as he even planned to change the name of the company after getting the hold lifted to get rid of the stigma. While i was incredibly disappointed, in thinking about it further, i'm not totally surprised that the FDA pushed the hold out further - again, multiple years of bad behavior, and 1 year of doing things right - they're still gun shy with us. But i feel like we were right there - and then Cyrus goes on leave. just really bad luck.

so, as you said, here we are. so critical to get this CEO hire right - someone who can continue to repair things with the FDA, bring business connections, etc. and while some have speculated that deals are being signed, holds lifted, etc. in the the background right now, i just don't buy it. just like life in general, we have to create the catalyst ourselves - finding the right CEO, getting the hold lifted, and finding a partner. if we can get some wins (even small incremental wins like those) the sky will begin to clear for us, and the SP will follow.



CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Concerns Rise Over Trump's Cryptocurrency Reserve Strategy

Updated Category News Views 192

Concerns About Cryptocurrency Announcements Prominent economist and market commentator Peter Schiff has urged a Congressional investigation into President Donald Trump's recent foray into cryptocurrency, suggesting that these announcements may involve insider trading and market manipulation. The Key Questions Raised In a recent post on X, Schiff sought answers to several...

Continue Reading
BriaCell Joins Prestigious Program to Boost Cancer Treatments

Updated Category News Views 145

BriaCell Enters MSK’s 2025 Therapeutics Accelerator Program BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, TSX: BCT) is thrilled to share the news of its selection into the Memorial Sloan Kettering Cancer Center (MSK) Therapeutics Accelerator Program for 2025. This prestigious program is designed to fast-track the clinical development of many innovative cancer...

Continue Reading
Exploring Current Net Asset Values of WisdomTree Funds

Updated Category News Views 114

Understanding Net Asset Value (NAV) in Investment Funds Net Asset Value (NAV) is a crucial metric for evaluating the performance of investment funds, representing the value of a fund's assets minus its liabilities. It's important for investors to keep track of NAV as it aids in making informed decisions regarding their investments. Here, we delve into the recent NAVs of...

Continue Reading
DoorDash's Innovative Tools Transforming Restaurant Dynamics

Updated Category News Views 208

Introduction to DoorDash's Expansion DoorDash (NASDAQ: DASH) has recently unveiled exciting developments regarding its Commerce Platform. This significant enhancement is set to assist restaurants in boosting direct sales while fostering better customer relationships across multiple channels. New Features for Restaurant Success The introduced tools are designed to uplift...

Continue Reading
Mezzion's Udenafil Shows Promise in ADPKD Study

Updated Category News Views 34

Positive News for Udenafil in Kidney Disease New updates from Mezzion Pharma Co., Ltd. have come across quite promising. They've reported some favorable results in a preclinical study of udenafil, targeting autosomal dominant polycystic kidney disease (ADPKD). It appears that this PDE5 inhibitor, typically used in aiding cardiovascular issues, now shows potential in...

Continue Reading